This document aims to provide guidance for civil society and non-governmental organisations (NGOs) as well as for national and regional authorities in the EU/EEA and the UK, who are providing support for people who have medical and social vulnerabilities during the COVID-19 pandemic.
This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This document aims to provide guidance to EU/EEA healthcare facilities and healthcare providers on infection prevention and control (IPC) measures for the management of suspected and confirmed cases of COVID-19 infection in healthcare settings, including long-term care facilities. It also offers guidance on the management of specimens at laboratories in the EU/EEA.
This document outlines operational considerations for how to support the continuity of national influenza surveillance systems and public health laboratories for the epidemiological and virological surveillance for influenza in the 2020–2021 season during the ongoing COVID-19 pandemic.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 3-9 March 2024 and includes updates on SARS-CoV-2 variant classification, sexually transmitted infections, Psittacosis cases, product safety recall of InterPharma Sodium Chloride 0.9% 30ml linked to Ralstonia pickettii contamination, cholera and Middle East respiratory syndrome coronavirus (MERS-CoV).
This document aims to help public health authorities in EU/EEA countries and the UK in their tracing and
management of persons, including healthcare workers, who have had contact with COVID-19 cases.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 April 2024 and includes updates on parvovirus B19 detections, cholera, chikungunya, dengue and poliomyelitis.
The purpose of this document is to review the evidence of COVID-19 vaccine effectiveness and duration of immunity following vaccination in adolescents aged 12-17 years, and to outline interim public health considerations for the potential use of a booster dose in this group.
The main aim of this activity is to collect information on the severity of breakthrough COVID-19 infections in outbreaks at long-term care facilities (LTCFs) and to obtain an estimate of relative risk of infection for vaccinated residents and staff members in these settings, by SARS-CoV-2 variant, vaccine product and number of vaccine doses.